What is RetinAI?
RetinAI operates as a sophisticated healthcare technology enterprise, bridging the gap between complex ophthalmic imaging and actionable clinical intelligence. Headquartered in Switzerland, the firm specializes in artificial intelligence-driven software solutions designed to streamline the collection, analysis, and utilization of eye-related medical data. Its flagship platform, Discovery, acts as a centralized hub for harmonizing diverse datasets, including optical coherence tomography scans and electronic health records.
By transforming raw medical data into structured, analytical insights, RetinAI empowers clinicians and researchers to make more informed decisions. The company occupies a critical niche in the digital health ecosystem, providing the necessary infrastructure to support pharmaceutical development and clinical care. Its commitment to data science and machine learning has established it as a pivotal player in the modernization of ophthalmology, facilitating a more efficient approach to the diagnosis and management of chronic eye diseases.
How much funding has RetinAI raised?
RetinAI has raised a total of $8M across 1 funding round:
Series B
$8M
Series B (2024): $8M with participation from THINC Ventures
Key Investors in RetinAI
THINC Ventures
A venture capital firm focused on supporting high-growth technology companies and innovative startups within the healthcare and digital infrastructure sectors.
What's next for RetinAI?
Looking ahead, the strategic deployment of this capital will likely focus on deepening the analytical capabilities of the Discovery platform and expanding its reach across international markets. As the company transitions through this growth phase, the emphasis will remain on scaling its machine learning models to handle increasingly complex datasets. This expansion is expected to drive further adoption among healthcare providers and pharmaceutical partners, reinforcing the company's role as a leader in the digital transformation of eye care. Future initiatives will likely prioritize the integration of new imaging modalities and the enhancement of predictive analytics, ensuring that RetinAI continues to deliver high-value solutions in an evolving medical landscape.
See full RetinAI company page
